### **NCI's Evolving Clinical Trials System**

# NCI Community Oncology Research Program (NCORP)

September 9, 2014

Worta McCaskill-Stevens, MD

Chief, Community Oncology and Prevention Trials Research Group


Division of Cancer Prevention

In Collaboration with NCI's Divisions of Cancer Control and Population
Sciences and Cancer Treatment & Diagnosis and the
Center to Reduce Cancer Health Disparities

U.S. DEPARTMENT OF HEALTH AND HUMAN SFRVICFS

National Institutes

### **NCORP** Milestones




# NCORP: A Single Community-Based National Network

- Clinical Trials: prevention, control, health-related quality of life, comparative effectiveness, and screening
- Cancer care delivery research: patient-provider and organization-level influences on cancer outcomes
- Incorporation of cancer disparities research into clinical trials and cancer care delivery research
- Accrual to National Clinical Trials Network (NCTN) treatment and imaging trials
- Community/academic partnerships
- 3 components: Community Sites, Minority/Underserved Community Sites and Research Bases


### **Research Bases**

Research Base Applicant	Institution (PI)	Research Focus & Strengths
Alliance	Mayo Clinic (Jan Buckner)	Chemoprevention risk assessment methods, tobacco harm reduction, disparities, natural history and risk identification of treated-related toxicities
SWOG	Oregon Health & Science University (Charles Blanke)	Biorepositories for prevention, Comparative effectiveness research
NRG	NRG Oncology Foundation, Inc. (Deb Bruner)	Risk reduction of women's cancers, radiation neurotoxicities, surgically-induced sequelae
ECOG-ACRIN	ECOG-ACRIN Medical Research Foundation (Lynn Wagner)	Imaging science, patient reported outcomes, symptom database
COG	Children's Hospital of Philadelphia (Brad Pollock)	Cancer-related infection, neurological sequelae, adolescents and young adults
URCC	University of Rochester (Gary Morrow)	Cancer-related fatigue in the elderly, treated-related cognitive dysfunction
Wake Forest	Wake Forest U. Health Sciences (Glenn Lesser)	Cardiotoxicity, radiation-related toxicities, transitions in care

# NCORP Community Site, MU Community Site and Research Bases Geographic and Organizational Diversity



# NCORP Community Site, MU Community Site and Research Bases Geographic and Organizational Diversity



## NCORP Clinical Trials and Health-Related quality of Life Studies

Туре	Focus
Cancer Prevention	Identify/evaluate interventions to reduce cancer risk and incidence
Cancer Control	Reduce incidence/co-morbidity of cancer and its treatment, enhance quality of life
Cancer Screening	Evaluate early diagnosis interventions and cancer recurrence
Health-Related Quality of Life	Embedded in NCTN Treatment Trials

# Research Agenda for Cancer Prevention, Control & Screening Trials

- Mechanisms of cancer-related symptoms
- Biomarkers of risk for treatment-related toxicities
- Molecularly targeted agents
- Post-treatment surveillance
- Management of precancerous lesions
- Enhance accrual of racial/ethnic and other under-represented populations
- Over-diagnosis and under-diagnosis

# Research Agenda for Cancer Prevention, Control & Screening Trials

### **Cardiotoxicity Task Force (Trans-NCI)**

Mission: To collaborate in prioritizing the cardio-oncology research agenda across the Research Bases within NCORP

**Goal:** To develop feasible, focused pragmatic research with meaningful clinical outcomes

# NCORP Cancer Care Delivery Potential Research Agenda

- Observational studies (Descriptive & Analytical)
  - Patterns of care or service utilization data
  - Alternate organizational structures (e.g., integrated healthcare systems versus free-standing hospitals)
  - Alternate multidisciplinary care planning models (e.g. tumor boards versus multi-disciplinary clinics)

#### Interventional studies

- Implementation of new technologies (e.g., decision-making tools)
- Incorporation of patient-reported information into clinical decision-making
- Implementation of new supportive/palliative care models
- Introduction of patient navigators

### NCORP FY 2014 Budget

#### **NCORP Funding**

**Grand Total: \$97.0 Million** 

\$91.1 Million allocation for NCORP grants

\$ 2.0 Million from DCCPS for NCORP grants (Additional FY 2014 NCI Funding)

\$ 93.1 Million

\$ 3.9 Million allocation for contract support for NCORP

#### **Details of NCORP grant funding**

NCORP Component	No. of Sites	Clinical Trials \$ Millions	CCDR Funding \$Millions	FY 2014 Total
NCORP & NCORP-M/U Sites SUBTOTAL:	46	\$42.7	\$ 7.5	\$50.3
NCORP Research Bases	7	\$38.2	\$ 4.5	\$42.8

#### **NCORP Supplemental Funding For Accrual**

\$2.9 M

### **Post Launch Activities**

- Cancer Care Delivery Research Planning Meeting
   August 25- 26, 2014
- September 22, 2014 Investigator/Administrators
   Meeting, Shady Grove
- Natural Experiments Working Group Develop research designs to evaluate natural experiments in the area of policy change and their effects on care and health outcomes

## Cancer Care Delivery Research (CCDR) Planning Meeting August 25-26, 20014

- Purpose: Begin foundational work for CCDR activities
  - Initiate process to develop CCDR strategic priorities
  - Prepare for the formation of Coordinating Committee
  - Begin discussions surrounding data infrastructure
- Attendees:
  - Research Base PIs and CCDR Leads
  - CCDR Leads from Community & Minority/Underserved Sites with enhanced CCDR capabilities
- Research Bases presented their CCDR research priorities and capacities
  - Clear evidence of innovation & expertise
- NCI presented "CCDR landscape" from national reports
- Four breakout discussions
  - Disparities, organization and system science, patient engagement, 'omics' in clinical practice

### **Early Next Steps for Cancer Care Delivery Research**

- Assemble initial Coordinating Committee members
- Determine leadership and additional members of Coordinating Committee
- Determine the structure of the CCDR Steering Committee
- Begin process for identifying CCDR research priorities and initiating working groups
- Characterize the health care environments and capacities for CCDR across NCORP

## NCORP: Advantages of a New Community-Based Research Organization

- Represents the "real world" of oncology practices
- Responsive to extensive stakeholder input
- Community Sites & Research Bases are better prepared to support the scientific agenda of NCORP
- Capacity to sustain or improve clinical trials accrual to all components of NCTN
- Broader base of individuals at risk of cancer
- Opportunity to evaluate the influence of the current health care system on the successful conduct and implementation of precision cancer therapy

### NCORP and CCOP Interim/Closeout Funding

#### **NCORP Funding**

Total: \$97.0 Million

\$91.1 Million allocation for NCORP grants

\$ 2.0 Million from DCCPS for NCORP grants (Additional FY 2014 NCI Funding)

\$ 3.9 Million allocation for contract support for NCORP

#### **CCOP Interim Funding**

**Total:** \$8.3 Million – Additional FY 2014 NCI Funding

#### **CCOP Closeout Funding**

Total: \$4.7 Million

\$2.9 Million – reserved by DCP

\$1.8 Million – Additional FY 2014 NCI Funding

#### FY 2014 Funding

Total: \$109.9 Million

# NCORP Community Site and Minority Site Geographic and Organizational Diversity

